X0609 4 2026-09-15 0001438533 Travere Therapeutics, Inc. TVTX 0001902368 Inrig Jula false C/O TRAVERE THERAPEUTICS, INC. 3611 VALLEY CENTRE DRIVE, SUITE 300 SAN DIEGO CA 92130 false true false false EVP, Head of R&D & CMO 1 Common Stock 2026-09-15 4 M 0 32395 8.93 A 145165 D Common Stock 2026-09-15 4 S 0 25390 62.0167 D 119775 D Common Stock 2026-09-15 4 S 0 17284 62.6242 D 102491 D Common Stock 2026-09-15 4 S 0 1600 63.6850 D 100891 D Common Stock 2026-09-15 4 S 0 400 65.31 D 100491 D Employee stock option (right to buy) 8.93 2026-09-15 4 M 0 32395 0 D 2034-01-31 Common Stock 32395 43605 D This sale was made pursuant to a written plan adopted on June 16, 2026, meeting the requirements of Rule 10b5-1(c) of the Securities Exchange Act of 1934, as amended. The weighted average sale price for the transaction reported was $62.0167, and the range of prices were between $61.40 and $62.39. Upon request by the SEC staff, the Issuer, or any security holder of the Issuer, full information regarding the number of shares sold at each price will be provided. The weighted average sale price for the transaction reported was $62.6242, and the range of prices were between $62.40 and $63.365. Upon request by the SEC staff, the Issuer, or any security holder of the Issuer, full information regarding the number of shares sold at each price will be provided. The weighted average sale price for the transaction reported was $63.685, and the range of prices were between $63.58 and $63.86. Upon request by the SEC staff, the Issuer, or any security holder of the Issuer, full information regarding the number of shares sold at each price will be provided. One-fourth of the shares subject to the stock option vest and become exercisable on the first anniversary of January 31, 2024, and the remaining shares vest in 36 equal monthly installments thereafter. /s/ Elizabeth E. Reed, Attorney-in-Fact 2026-09-17